An AI solution designed to detect adverse drug reactions was working exactly as intended. The science held up and the model achieved approximately 85% accuracy. When it reached compliance review, however, the project stalled because the team could not demonstrate the audit trails and data lineage regulators required. The result was an 18-month refactoring effort that cost $1.2 million. The experience exposed a problem that continues to derail life sciences AI: without evidence, even successful models fail to reach production.
“The science was not a problem,” recalls Tarini Mohapatra, Chief Executive Officer and Co-Founder of TFives. “There was nothing wrong with the technology. In regulated life sciences, however accurate, without evidence it’s not an asset. It becomes a liability.” That experience reshaped Mohapatra’s thinking about compliance architecture. Rather than treating governance as a final checkpoint, he came to believe it must become part of the foundation. The organizations that consistently move faster through regulatory review are not those attempting to minimize compliance. They are the ones embedding compliance into architecture from the very beginning.
Compliance Architecture Starts Before the First Line of Code
This philosophy represents a shift from reactive documentation to compliance-by-design, where governance maturity, regulatory alignment, and compliance infrastructure evolve alongside product development. Every decision, approval, AI recommendation, and workflow handoff contributes to evidence that is captured as work happens rather than reconstructed months later.
“We realized every submission for compliance readiness became an archaeological problem,” Mohapatra says. “The evidence which does not exist at the point of first decision, you just can’t create it at the end.” Compliance should no longer be viewed as documentation prepared for regulators. It becomes operational infrastructure that enables innovation instead of delaying it.
Bridging Deterministic Rules and Probabilistic AI
One of the defining challenges facing regulated AI is the collision between probabilistic AI and deterministic regulatory frameworks. AI systems naturally generate variable outcomes, while regulators expect consistency, traceability, and reproducibility. This tension is often misunderstood as a technology limitation when it is fundamentally an architectural challenge. Success depends on bridging deterministic rules and probabilistic AI through governance mechanisms that make every AI-assisted decision explainable. In practice, that means capturing the specific model version behind each output, the human who approved it, and the rule it was checked against, each timestamped and preserved as a permanent record.
“The regulators are not asking pharma to pretend that humans are gone,” Mohapatra says. “They’re asking, prove the loop is governed, traceable and reconstructible.” This approach places human oversight at the center of every AI workflow while maintaining continuous evidence trails. Every AI generation, every approval, every rule check, and every system handoff contributes to a permanent governance record. Instead of viewing compliance as an interruption, organizations can achieve compliance as real-time infrastructure, allowing teams to maintain speed while reducing non-conformance risk.
Embedding Compliance Into the Workflow
Many organizations still approach governance as an episodic event instead of an operational discipline, and that creates unnecessary delays because compliance teams are forced to reconstruct decisions after development is complete. Mohapatra’s alternative focuses on building governance into the workflow, where responsibility is shared across business, technology, quality, and regulatory teams from day one. “They stop treating governance as something at the end,” he says. “The responsibility for compliance and governance becomes embedded and a responsibility of every team member.”
He compares the process to a professional kitchen. Great chefs continuously taste and adjust dishes throughout preparation rather than waiting until the meal reaches the customer. Life sciences organizations should apply the same principle by validating decisions continuously throughout development instead of relying on one final inspection. The result is shorter review cycles, stronger evidence trails, greater regulatory velocity, and a culture where validation becomes part of everyday work rather than a last-minute exercise.
Why Life Sciences AI Fails in Production
For Mohapatra, the $1.2 million lesson was proof that innovation succeeds only when evidence is designed alongside intelligence. As regulated AI becomes central to life sciences, the future belongs to organizations that treat compliance not as a destination, but as architecture. “Accuracy will not work,” he says. “Even if it is 85% accurate, a model will not get approved to go into production. It is about governance.” As regulators continue emphasizing replayability, explainability, and human accountability, organizations must rethink the entire molecule-to-market compliance lifecycle. Competitive advantage will increasingly come from turning regulatory requirements into product advantage rather than treating them as obstacles.
The companies that succeed will understand how to move faster in regulated work by creating systems capable of real-time regulatory alignment from the first design decision through commercialization. Governance, evidence, and accountability cease to be administrative burdens and instead become strategic capabilities that accelerate innovation while building trust with regulators.
Follow Tarini Mohapatra on LinkedIn or visit his website for more insights on AI governance, compliance, and regulated innovation.
